AU2013371146C1 - 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same - Google Patents

2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same Download PDF

Info

Publication number
AU2013371146C1
AU2013371146C1 AU2013371146A AU2013371146A AU2013371146C1 AU 2013371146 C1 AU2013371146 C1 AU 2013371146C1 AU 2013371146 A AU2013371146 A AU 2013371146A AU 2013371146 A AU2013371146 A AU 2013371146A AU 2013371146 C1 AU2013371146 C1 AU 2013371146C1
Authority
AU
Australia
Prior art keywords
phenyl
methyl
compound
imidazol
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013371146A
Other languages
English (en)
Other versions
AU2013371146A1 (en
AU2013371146B2 (en
Inventor
Hyun Ju Cha
Joong Myung Cho
Yong Rae Hong
Sool Ki Kwon
Im Sook MIN
Jeong Eun Na
Seonggu Ro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CrystalGenomics Inc
Original Assignee
CrystalGenomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CrystalGenomics Inc filed Critical CrystalGenomics Inc
Publication of AU2013371146A1 publication Critical patent/AU2013371146A1/en
Application granted granted Critical
Publication of AU2013371146B2 publication Critical patent/AU2013371146B2/en
Priority to AU2018214134A priority Critical patent/AU2018214134B2/en
Publication of AU2013371146C1 publication Critical patent/AU2013371146C1/en
Priority to AU2020201431A priority patent/AU2020201431B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013371146A 2012-12-28 2013-12-26 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same Active AU2013371146C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018214134A AU2018214134B2 (en) 2012-12-28 2018-08-10 2,3-dihydro-isoindol-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same
AU2020201431A AU2020201431B2 (en) 2012-12-28 2020-02-27 2,3-dihydro-isoindol-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261746980P 2012-12-28 2012-12-28
US61/746,980 2012-12-28
PCT/KR2013/012204 WO2014104757A1 (ko) 2012-12-28 2013-12-26 Btk 키나아제 억제제로서의 2,3-디하이드로-이소인돌-1-온 유도체 및 이를 함유하는 약학적 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018214134A Division AU2018214134B2 (en) 2012-12-28 2018-08-10 2,3-dihydro-isoindol-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same

Publications (3)

Publication Number Publication Date
AU2013371146A1 AU2013371146A1 (en) 2015-07-16
AU2013371146B2 AU2013371146B2 (en) 2018-05-10
AU2013371146C1 true AU2013371146C1 (en) 2019-01-17

Family

ID=51021712

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013371146A Active AU2013371146C1 (en) 2012-12-28 2013-12-26 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same
AU2018214134A Active AU2018214134B2 (en) 2012-12-28 2018-08-10 2,3-dihydro-isoindol-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same
AU2020201431A Active AU2020201431B2 (en) 2012-12-28 2020-02-27 2,3-dihydro-isoindol-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018214134A Active AU2018214134B2 (en) 2012-12-28 2018-08-10 2,3-dihydro-isoindol-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same
AU2020201431A Active AU2020201431B2 (en) 2012-12-28 2020-02-27 2,3-dihydro-isoindol-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same

Country Status (15)

Country Link
US (4) US9758508B2 (enExample)
EP (2) EP2940014B1 (enExample)
JP (2) JP6325573B2 (enExample)
KR (1) KR102009163B1 (enExample)
CN (1) CN104995184B (enExample)
AU (3) AU2013371146C1 (enExample)
BR (1) BR112015015477B1 (enExample)
CA (1) CA2896711C (enExample)
DK (1) DK2940014T3 (enExample)
ES (2) ES2696700T3 (enExample)
MX (2) MX386542B (enExample)
PL (1) PL2940014T3 (enExample)
PT (1) PT2940014T (enExample)
RU (2) RU2018138028A (enExample)
WO (1) WO2014104757A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
DK2940014T3 (en) * 2012-12-28 2018-12-10 Crystalgenomics Inc 2,3-DIHYDRO-ISOINDOL-1-ON DERIVATIVE AS BTK KINase INHIBITORS AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
KR20190128646A (ko) * 2017-02-21 2019-11-18 압토스 바이오사이언시스 인코포레이티드 혈액 종양 환자들의 치료 방법
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
US20200171001A1 (en) * 2018-11-30 2020-06-04 Aptose Biosciences Inc. Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
US20240091226A1 (en) * 2021-01-05 2024-03-21 Sumitomo Pharma Oncology, Inc. Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitor
CN117295737A (zh) * 2021-03-05 2023-12-26 林伯士萨顿公司 Hpk1拮抗剂和其用途
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012047017A2 (ko) * 2010-10-05 2012-04-12 크리스탈지노믹스(주) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1379511B1 (en) * 2001-04-12 2005-07-20 F. Hoffmann-La Roche Ag DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
WO2004108672A1 (en) * 2003-06-02 2004-12-16 Abbott Laboratories Isoindolin-1-one compounds as kinase inhibitors
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
KR20080011199A (ko) * 2005-04-19 2008-01-31 교와 핫꼬 고교 가부시끼가이샤 질소 함유 복소환 화합물
US20070161648A1 (en) * 2005-10-14 2007-07-12 Hughes Terry V Substituted dihydro-isoindolones useful in treating kinase disorders
WO2007107469A1 (en) * 2006-03-20 2007-09-27 F. Hoffmann-La Roche Ag Methods of inhibiting btk and syk protein kinases
JPWO2008047831A1 (ja) * 2006-10-17 2010-02-25 協和発酵キリン株式会社 Ｊａｋ阻害剤
JP5587193B2 (ja) * 2007-10-23 2014-09-10 エフ．ホフマン−ラ ロシュ アーゲー 新規なキナーゼ阻害剤
WO2012014017A1 (en) 2010-07-30 2012-02-02 Poly Medicure Limited Catheter introducer
DK2940014T3 (en) 2012-12-28 2018-12-10 Crystalgenomics Inc 2,3-DIHYDRO-ISOINDOL-1-ON DERIVATIVE AS BTK KINase INHIBITORS AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012047017A2 (ko) * 2010-10-05 2012-04-12 크리스탈지노믹스(주) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물

Also Published As

Publication number Publication date
KR20160058720A (ko) 2016-05-25
US20170362205A1 (en) 2017-12-21
JP6596537B2 (ja) 2019-10-23
CN104995184A (zh) 2015-10-21
AU2018214134B2 (en) 2020-03-12
CN104995184B (zh) 2018-01-02
EP2940014B1 (en) 2018-09-26
JP6325573B2 (ja) 2018-05-16
HK1259355A1 (en) 2019-11-29
KR102009163B1 (ko) 2019-08-09
ES2696700T3 (es) 2019-01-17
JP2016504351A (ja) 2016-02-12
BR112015015477A2 (pt) 2017-07-11
BR112015015477B1 (pt) 2022-07-12
PL2940014T3 (pl) 2019-03-29
US20220380346A1 (en) 2022-12-01
RU2018138028A (ru) 2019-03-21
US10604508B2 (en) 2020-03-31
RU2015124381A (ru) 2017-02-01
PT2940014T (pt) 2018-11-28
DK2940014T3 (en) 2018-12-10
AU2020201431A1 (en) 2020-03-19
EP3428161A1 (en) 2019-01-16
EP3428161B1 (en) 2022-09-07
AU2018214134A1 (en) 2018-08-30
MX2021011563A (es) 2022-10-10
WO2014104757A1 (ko) 2014-07-03
ES2929906T3 (es) 2022-12-02
US20150336934A1 (en) 2015-11-26
AU2013371146A1 (en) 2015-07-16
EP2940014A1 (en) 2015-11-04
RU2671847C2 (ru) 2018-11-07
US9758508B2 (en) 2017-09-12
CA2896711A1 (en) 2014-07-03
US11230539B2 (en) 2022-01-25
MX386542B (es) 2025-03-18
JP2018109069A (ja) 2018-07-12
CA2896711C (en) 2019-12-31
EP2940014A4 (en) 2016-06-22
AU2020201431B2 (en) 2021-07-22
MX2015008396A (es) 2016-04-15
AU2013371146B2 (en) 2018-05-10
US20210009565A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
AU2020201431B2 (en) 2,3-dihydro-isoindol-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same
CN107141288B (zh) 一类吴茱萸碱类化合物及其制备方法与应用
WO2018084321A1 (ja) Ｅｇｆｒ阻害及び腫瘍治療に有用な新規化合物
WO2009049492A1 (en) N-substituted aromatic hydrocarbon aniline and multi-substituted diarylether compounds, the preparation and the use of antitumor thereof
CN110357905B (zh) 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途
US11572359B2 (en) PARP/PI3K double-target inhibit containing pyridopyrimidine structure
WO2019096112A1 (zh) 一种取代的苯并咪唑化合物及包含该化合物的组合物
CN105228609A (zh) 新的转录因子调节剂
CN115353489B (zh) 一种氘代酰胺类衍生物及其应用
HK1259355B (en) 2,3-dihydro-isoindole-1-one derivative as btk kinase suppressant, and pharmaceutical composition including same
JP2024510520A (ja) ダブルリング雑環ｆｇｆｒ４阻害剤、ダブルリング雑環ｆｇｆｒ４阻害剤を含有する医薬組成物と製剤、及びその用途
US12606551B2 (en) Salt of tetrahydroisoquinoline derivative, preparation method therefor, and medical use thereof
US10040803B2 (en) 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors
WO2025149623A1 (en) Wnk1 inhibitors
EP4671245A1 (en) HETEROAROMATIC CYCLIC COMPOUND SERVING AS A CDK7 KINASE INHIBITOR, ITS PREPARATION AND USE
WO2021147790A1 (zh) 吡唑并[1,5-a]吡嗪类衍生物及其制备方法和用途

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 24 SEP 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 24 SEP 2018

FGA Letters patent sealed or granted (standard patent)